Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion

Lung Cancer. 2021 Mar:153:174-175. doi: 10.1016/j.lungcan.2021.01.001. Epub 2021 Jan 8.

Authors

ZhiFeng Li¹, Yingcheng Lin¹, Xiuying Chi¹, Mian Xu², Hongbiao Wang³

Affiliations

¹ Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.
² OrigiMed, Shanghai, China.
³ Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China. Electronic address: wanghongbiao123@qq.com.

PMID: 33472762
DOI: 10.1016/j.lungcan.2021.01.001

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Crizotinib / pharmacology
Crizotinib / therapeutic use
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Oncogene Proteins, Fusion / genetics
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / genetics
Proto-Oncogene Proteins / genetics
Receptor Protein-Tyrosine Kinases / genetics

Substances

Oncogene Proteins, Fusion
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Crizotinib
Protein-Tyrosine Kinases
ROS1 protein, human
Receptor Protein-Tyrosine Kinases